<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20240411021122
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20240411021122" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 11 Apr 2024 06:11:23 +0000</lastbuilddate>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Discordant Aortic Stenosis Parameters in Real-World Data: Do Not Ignore a Low Aortic Valve Area</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599723/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):e153. doi: 10.1016/j.jacc.2023.12.041.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599723/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599723</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.041>10.1016/j.jacc.2023.12.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599723</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew D Solomon</dc:creator>
<dc:creator>Anthony Demaria</dc:creator>
<dc:creator>Rick Nishimura</dc:creator>
<dc:creator>Femi Philip</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Discordant Aortic Stenosis Parameters in Real-World Data: Do Not Ignore a Low Aortic Valve Area</dc:title>
<dc:identifier>pmid:38599723</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.041</dc:identifier>
</item>
<item>
<title>Treatment and Prognosis of Less Than Severe Aortic Stenosis: The Importance of Context</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599722/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):e151. doi: 10.1016/j.jacc.2023.12.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599722/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599722</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.042>10.1016/j.jacc.2023.12.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599722</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Wael A Jaber</dc:creator>
<dc:creator>L Leonardo Rodriguez</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Treatment and Prognosis of Less Than Severe Aortic Stenosis: The Importance of Context</dc:title>
<dc:identifier>pmid:38599722</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.042</dc:identifier>
</item>
<item>
<title>Effect of Personalized Accelerated Pacing in Patients With Nonobstructive Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599721/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1492-1493. doi: 10.1016/j.jacc.2024.01.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599721/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599721</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.036>10.1016/j.jacc.2024.01.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599721</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Sana Riaz</dc:creator>
<dc:creator>Sean R McMahon</dc:creator>
<dc:creator>Katherine Stockey</dc:creator>
<dc:creator>Markus Meyer</dc:creator>
<dc:creator>Adaya Weissler-Snir</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Personalized Accelerated Pacing in Patients With Nonobstructive Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38599721</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.036</dc:identifier>
</item>
<item>
<title>Realizing Our Vision: ACC's Next 5-Year Strategic Plan</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599720/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1489-1491. doi: 10.1016/j.jacc.2024.03.366.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599720/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599720</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.366>10.1016/j.jacc.2024.03.366</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599720</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Cathleen Biga</dc:creator>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Realizing Our Vision: ACC's Next 5-Year Strategic Plan</dc:title>
<dc:identifier>pmid:38599720</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.366</dc:identifier>
</item>
<item>
<title>Recent Insights Into Native Valve Infective Endocarditis: JACC Focus Seminar 4/4</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599719/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>This focused review highlights the latest issues in native valve infective endocarditis. Native valve disease moderately increases the risk of developing infective endocarditis. In 2023, new diagnostic criteria were published by the Duke-International Society of Cardiovascular Infectious Diseases group. New pathogens were designated as typical, and findings on computed tomography imaging were included as diagnostic criteria. It is now recognized that a multidisciplinary approach to care is...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1431-1443. doi: 10.1016/j.jacc.2023.12.043.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This focused review highlights the latest issues in native valve infective endocarditis. Native valve disease moderately increases the risk of developing infective endocarditis. In 2023, new diagnostic criteria were published by the Duke-International Society of Cardiovascular Infectious Diseases group. New pathogens were designated as typical, and findings on computed tomography imaging were included as diagnostic criteria. It is now recognized that a multidisciplinary approach to care is vital, and the role of an "endocarditis team" is highlighted. Recent studies have suggested that a transition from intravenous to oral antibiotics in selected patients may be reasonable, and the role of long-acting antibiotics is discussed. It is also now clear that an aggressive surgical approach can be life-saving in some patients. Finally, results of several recent studies have suggested there is an association between dental and other invasive procedures and an increased risk of developing infective endocarditis. Moreover, data indicate that antibiotic prophylaxis may be effective in some scenarios.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599719/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599719</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.043>10.1016/j.jacc.2023.12.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599719</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mark J Dayer</dc:creator>
<dc:creator>Juan A Quintero-Martinez</dc:creator>
<dc:creator>Martin H Thornhill</dc:creator>
<dc:creator>John B Chambers</dc:creator>
<dc:creator>Gosta B Pettersson</dc:creator>
<dc:creator>Larry M Baddour</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Recent Insights Into Native Valve Infective Endocarditis: JACC Focus Seminar 4/4</dc:title>
<dc:identifier>pmid:38599719</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.043</dc:identifier>
</item>
<item>
<title>The Clinical Challenge of Prosthetic Valve Endocarditis: JACC Focus Seminar 3/4</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>During the past 6 decades, there have been numerous changes in prosthetic valve endocarditis (PVE), currently affecting an older population and increasing in incidence in patients with transcatheter-implanted valves. Significant microbiologic (molecular biology) and imaging diagnostic (fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography) advances have been incorporated into the 2023 Duke-International Society for Cardiovascular Infectious Diseases infective...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1418-1430. doi: 10.1016/j.jacc.2024.01.037.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">During the past 6 decades, there have been numerous changes in prosthetic valve endocarditis (PVE), currently affecting an older population and increasing in incidence in patients with transcatheter-implanted valves. Significant microbiologic (molecular biology) and imaging diagnostic (fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography) advances have been incorporated into the 2023 Duke-International Society for Cardiovascular Infectious Diseases infective endocarditis diagnostic criteria, thus increasing the diagnostic sensitivity for PVE without sacrificing specificity in validation studies. PVE is a life-threatening disease requiring management by multidisciplinary endocarditis teams in cardiac centers to improve outcomes. Novel surgical options are now available, and an increasing set of patients may avoid surgical intervention despite indication. Selected patients may complete parenteral or oral antimicrobial treatment at home. Finally, patients with prosthetic valves implanted surgically or by the transcatheter approach are candidates for antibiotic prophylaxis before invasive dental procedures.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599718</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.037>10.1016/j.jacc.2024.01.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599718</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Guillermo Cuervo</dc:creator>
<dc:creator>Eduard Quintana</dc:creator>
<dc:creator>Ander Regueiro</dc:creator>
<dc:creator>Andrés Perissinotti</dc:creator>
<dc:creator>Barbara Vidal</dc:creator>
<dc:creator>Jose M Miro</dc:creator>
<dc:creator>Larry M Baddour</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Clinical Challenge of Prosthetic Valve Endocarditis: JACC Focus Seminar 3/4</dc:title>
<dc:identifier>pmid:38599718</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.037</dc:identifier>
</item>
<item>
<title>Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1415-1417. doi: 10.1016/j.jacc.2024.03.002. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599717</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.002>10.1016/j.jacc.2024.03.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599717</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Luke J Burchill</dc:creator>
<dc:creator>C Charles Jain</dc:creator>
<dc:creator>William R Miranda</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure</dc:title>
<dc:identifier>pmid:38599717</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.002</dc:identifier>
</item>
<item>
<title>SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599716/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1399-1402. doi: 10.1016/j.jacc.2024.02.028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599716/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599716</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.028>10.1016/j.jacc.2024.02.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599716</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic</dc:title>
<dc:identifier>pmid:38599716</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.028</dc:identifier>
</item>
<item>
<title>Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599715/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Physiological-adaptive water conservation eliminated the expected osmotic diuretic potential of dapagliflozin and thereby prevented a glucose-driven increase in urine volume of approximately 10 mL/kg/d · 75 kg = 750 mL/kg/d. (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment [DAPA-Shuttle1]; NCT04080518).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1386-1398. doi: 10.1016/j.jacc.2024.02.020.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sodium-glucose cotransporter 2 inhibitors are believed to improve cardiac outcomes due to their osmotic diuretic potential.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to test the hypothesis that vasopressin-driven urine concentration overrides the osmotic diuretic effect of glucosuria induced by dapagliflozin treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: DAPA-Shuttle1 (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment) was a single-center, double-blind, randomized, placebo-controlled trial, in which patients with chronic heart failure NYHA functional classes I/II and reduced ejection fraction were randomly assigned to receive dapagliflozin 10 mg daily or placebo (1:1) for 4 weeks. The primary endpoint was change from baseline in urine osmolyte concentration. Secondary endpoints included changes in copeptin levels and solute free water clearance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Thirty-three randomized, sodium-glucose cotransporter 2 inhibitor-naïve participants completed the study, 29 of whom (placebo: n = 14; dapagliflozin: n = 15) provided accurate 24-hour urine collections (mean age 59 ± 14 years; left ventricular ejection fraction 31% ± 9%). Dapagliflozin treatment led to an isolated increase in urine glucose excretion by 3.3 mmol/kg/d (95% CI: 2.51-4.04; P &lt; 0.0001) within 48 hours (early) which persisted after 4 weeks (late; 2.7 mmol/kg/d [95% CI: 1.98-3.51]; P &lt; 0.0001). Dapagliflozin treatment increased serum copeptin early (5.5 pmol/L [95% CI: 0.45-10.5]; P &lt; 0.05) and late (7.8 pmol/L [95% CI: 2.77-12.81]; P &lt; 0.01), leading to proportional reductions in free water clearance (early: -9.1 mL/kg/d [95% CI: -14 to -4.12; P &lt; 0.001]; late: -11.0 mL/kg/d [95% CI: -15.94 to -6.07; P &lt; 0.0001]) and elevated urine concentrations (late: 134 mmol/L [95% CI: 39.28-229.12]; P &lt; 0.01). Therefore, urine volume did not significantly increase with dapagliflozin (mean difference early: 2.8 mL/kg/d [95% CI: -1.97 to 7.48; P = 0.25]; mean difference late: 0.9 mL/kg/d [95% CI: -3.83 to 5.62]; P = 0.70).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Physiological-adaptive water conservation eliminated the expected osmotic diuretic potential of dapagliflozin and thereby prevented a glucose-driven increase in urine volume of approximately 10 mL/kg/d · 75 kg = 750 mL/kg/d. (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment [DAPA-Shuttle1]; NCT04080518).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599715/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599715</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.020>10.1016/j.jacc.2024.02.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599715</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Adriana Marton</dc:creator>
<dc:creator>Seyed Ehsan Saffari</dc:creator>
<dc:creator>Manfred Rauh</dc:creator>
<dc:creator>Ruo-Ning Sun</dc:creator>
<dc:creator>Armin M Nagel</dc:creator>
<dc:creator>Peter Linz</dc:creator>
<dc:creator>Tzy Tiing Lim</dc:creator>
<dc:creator>Kaoru Takase-Minegishi</dc:creator>
<dc:creator>Anastacia Pajarillaga</dc:creator>
<dc:creator>Sharon Saw</dc:creator>
<dc:creator>Norihiko Morisawa</dc:creator>
<dc:creator>Wan Keat Yam</dc:creator>
<dc:creator>Shintaro Minegishi</dc:creator>
<dc:creator>John J Totman</dc:creator>
<dc:creator>Serena Teo</dc:creator>
<dc:creator>Louis L Y Teo</dc:creator>
<dc:creator>Choon Ta Ng</dc:creator>
<dc:creator>Kento Kitada</dc:creator>
<dc:creator>Johannes Wild</dc:creator>
<dc:creator>Jean-Paul Kovalik</dc:creator>
<dc:creator>Friedrich C Luft</dc:creator>
<dc:creator>Peter J Greasley</dc:creator>
<dc:creator>Calvin W L Chin</dc:creator>
<dc:creator>David K L Sim</dc:creator>
<dc:creator>Jens Titze</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure</dc:title>
<dc:identifier>pmid:38599715</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.020</dc:identifier>
</item>
<item>
<title>Modulation of Antiplatelet Therapy in PCI-Treated Patients: A Rocky Road Toward More Individualized Treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1382-1385. doi: 10.1016/j.jacc.2024.03.355.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599714</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.355>10.1016/j.jacc.2024.03.355</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599714</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Dirk Sibbing</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Modulation of Antiplatelet Therapy in PCI-Treated Patients: A Rocky Road Toward More Individualized Treatment</dc:title>
<dc:identifier>pmid:38599714</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.355</dc:identifier>
</item>
<item>
<title>Effectiveness of Clopidogrel vs Alternative P2Y&lt;sub>;12&lt;/sub>; Inhibitors Based on the ABCD-GENE Score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These data support the use of alternative therapy over clopidogrel in CYP2C19 LOF allele carriers after PCI, regardless of ABCD-GENE score, while clopidogrel is as effective as alternative therapy in non-LOF patients with scores &lt;10.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1370-1381. doi: 10.1016/j.jacc.2024.02.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: An ABCD-GENE (age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genetic variants) score ≥10 predicts reduced clopidogrel effectiveness, but its association with response to alternative therapy remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to evaluate the association between ABCD-GENE score and the effectiveness of clopidogrel vs alternative P2Y<sub>12</sub> inhibitor (prasugrel or ticagrelor) therapy after percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 4,335 patients who underwent PCI, CYP2C19 genotyping, and P2Y<sub>12</sub> inhibitor treatment were included. The primary outcome was major atherothrombotic events (MAE) within 1 year after PCI. Cox regression was performed to assess event risk in clopidogrel-treated (reference) vs alternatively treated patients, with stabilized inverse probability weights derived from exposure propensity scores after stratifying by ABCD-GENE score and further by CYP2C19 loss-of-function (LOF) genotype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among patients with scores &lt;10 (n = 3,200), MAE was not different with alternative therapy vs clopidogrel (weighted HR: 0.89; 95% CI: 0.65-1.22; P = 0.475). The risk for MAE also did not significantly differ by treatment among patients with scores ≥10 (n = 1,135; weighted HR: 0.75; 95% CI: 0.51-1.11; P = 0.155). Among CYP2C19 LOF allele carriers, MAE risk appeared lower with alternative therapy in both the group with scores &lt;10 (weighted HR: 0.50; 95% CI: 0.25-1.01; P = 0.052) and the group with scores ≥10 (weighted HR: 0.48; 95% CI: 0.29-0.80; P = 0.004), while there was no difference in the group with scores &lt;10 and no LOF alleles (weighted HR: 1.03; 95% CI: 0.70-1.51; P = 0.885).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These data support the use of alternative therapy over clopidogrel in CYP2C19 LOF allele carriers after PCI, regardless of ABCD-GENE score, while clopidogrel is as effective as alternative therapy in non-LOF patients with scores &lt;10.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599713</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.015>10.1016/j.jacc.2024.02.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599713</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Cameron D Thomas</dc:creator>
<dc:creator>Francesco Franchi</dc:creator>
<dc:creator>Joseph S Rossi</dc:creator>
<dc:creator>Ellen C Keeley</dc:creator>
<dc:creator>R David Anderson</dc:creator>
<dc:creator>Amber L Beitelshees</dc:creator>
<dc:creator>Julio D Duarte</dc:creator>
<dc:creator>Luis Ortega-Paz</dc:creator>
<dc:creator>Yan Gong</dc:creator>
<dc:creator>Richard A Kerensky</dc:creator>
<dc:creator>Natasha Kulick</dc:creator>
<dc:creator>Caitrin W McDonough</dc:creator>
<dc:creator>Anh B Nguyen</dc:creator>
<dc:creator>Yehua Wang</dc:creator>
<dc:creator>Marshall Winget</dc:creator>
<dc:creator>William E Yang</dc:creator>
<dc:creator>Julie A Johnson</dc:creator>
<dc:creator>Almut G Winterstein</dc:creator>
<dc:creator>George A Stouffer</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Craig R Lee</dc:creator>
<dc:creator>Larisa H Cavallari</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effectiveness of Clopidogrel vs Alternative P2Y&lt;sub>;12&lt;/sub>; Inhibitors Based on the ABCD-GENE Score</dc:title>
<dc:identifier>pmid:38599713</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.015</dc:identifier>
</item>
<item>
<title>Unlocking the Gates of ISCHEMIA: Moving Toward Personalized Angina Management for Chronic Coronary Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599712/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1367-1369. doi: 10.1016/j.jacc.2024.03.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599712/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599712</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.001>10.1016/j.jacc.2024.03.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599712</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Josip Andelo Borovac</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Unlocking the Gates of ISCHEMIA: Moving Toward Personalized Angina Management for Chronic Coronary Syndrome</dc:title>
<dc:identifier>pmid:38599712</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.001</dc:identifier>
</item>
<item>
<title>Variation in Health Status With Invasive vs Conservative Management of Chronic Coronary Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599711/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the management of chronic coronary disease, individual patient characteristics are associated with 1-year health status, with younger age and poorer angina-related health status showing greater benefit from invasive management. This prediction algorithm can support the translation of the ISCHEMIA trial results to individual patients. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1353-1366. doi: 10.1016/j.jacc.2024.02.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The ISCHEMIA trial found that patients with chronic coronary disease randomized to invasive strategy had better health status than those randomized to conservative strategy. It is unclear how best to translate these population-level results to individual patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to identify patient characteristics associated with health status from invasive and conservative strategies, and develop a prediction algorithm for shared decision-making.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: One-year disease-specific health status was assessed in ISCHEMIA with the Seattle Angina Questionnaire (SAQ) Summary Score (SAQ SS) and Angina Frequency, Physical Limitations (PL), and Quality of Life (QL) domains (range 0-100, higher = less angina/better health status).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4,617 patients from 320 sites in 37 countries, mean SAQ SS was 74.1 ± 18.9 at baseline and 85.7 ± 15.6 at 1 year. Lower baseline SAQ SS and younger age were associated with better 1-year health status with invasive strategy (P interaction = 0.009 and P interaction = 0.004, respectively). For the individual domains, there were significant treatment interactions for baseline SAQ score (Angina Frequency, PL), age (PL, QL), anterior ischemia (PL), and number of baseline antianginal medications (QL), with more benefit of invasive in patients with worse baseline health status, younger age, anterior ischemia, and on more antianginal medications. Parsimonious prediction models were developed for 1-year SAQ domains with invasive or conservative strategies to support shared decision-making.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the management of chronic coronary disease, individual patient characteristics are associated with 1-year health status, with younger age and poorer angina-related health status showing greater benefit from invasive management. This prediction algorithm can support the translation of the ISCHEMIA trial results to individual patients. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599711/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599711</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.019>10.1016/j.jacc.2024.02.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599711</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Philip G Jones</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Daniel B Mark</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>Jiyan Chen</dc:creator>
<dc:creator>Jonathan D Newman</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>ISCHEMIA Research Group</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Variation in Health Status With Invasive vs Conservative Management of Chronic Coronary Disease</dc:title>
<dc:identifier>pmid:38599711</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.019</dc:identifier>
</item>
<item>
<title>A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this actual use study, a technology assisted Web App allowed >;90% of consumers to correctly self-select for statin use and achieve clinically important LDL-C reductions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)06686-5. doi: 10.1016/j.jacc.2024.03.388. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although statins reduce adverse cardiovascular outcomes, less than half of eligible patients receive treatment. A nonprescription statin has the potential to improve access to statins.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To assess concordance between clinician and consumer assessment of eligibility for nonprescription statin treatment using a Technology Assisted Self-Selection (TASS) Web Application (Web App) and evaluate effect on low-density lipoprotein cholesterol (LDL-C) levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A prospective actual use 6-month study to evaluate use of a Web App to qualify participants without a medical background for a moderate intensity statin based on current guidelines. Participants entered demographic information, cholesterol values, blood pressure and concomitant medications into the Web App, resulting in three possible outcomes- "Do Not Use," "Ask a Doctor" or "OK to Use".</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 1196 participants, median age 63 (IQR, 57-68), 39.6% women, 79.3% White, 11.7% Black, and 4.1% with limited literacy. Mean LDL-C was 139.6 mg/dL (SD, 28.3) and median calculated 10-year risk of atherosclerotic cardiovascular disease was 10.1% (IQR, 7.3-14.0). Initial Web App self-selection resulted in an outcome concordant with clinician assessment in 90.7% (95% CI, 88.9-92.3) of participants and 98.1% (95% CI, 97.1-98.8) had a concordant final use outcome during treatment. Mean percent change in LDL-C was -35.5% (95% CI, -36.6 to -34.3). Serious adverse events occurred in 27 (2.3%) participants, none related to study drug.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this actual use study, a technology assisted Web App allowed >;90% of consumers to correctly self-select for statin use and achieve clinically important LDL-C reductions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599257</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.388>10.1016/j.jacc.2024.03.388</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599257</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Steven E Nissen</dc:creator>
<dc:creator>Howard G Hutchinson</dc:creator>
<dc:creator>Kathy Wolski</dc:creator>
<dc:creator>Karol Watson</dc:creator>
<dc:creator>Seth S Martin</dc:creator>
<dc:creator>Erin D Michos</dc:creator>
<dc:creator>William S Weintraub</dc:creator>
<dc:creator>Melanie Morris</dc:creator>
<dc:creator>Leslie Cho</dc:creator>
<dc:creator>Luke Laffin</dc:creator>
<dc:creator>Douglas Jacoby</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Jan Ekelund</dc:creator>
<dc:creator>Filip Birve</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>Michelle Strzelecki</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication</dc:title>
<dc:identifier>pmid:38599257</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.388</dc:identifier>
</item>
<item>
<title>Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599256/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In symptomatic nHCM, novel drug therapy targeting myocardial energetics was safe and well tolerated and associated with better exercise performance and health status among those most symptomatically limited. The findings support assessing ninerafaxstat in a Phase 3 study.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)06684-1. doi: 10.1016/j.jacc.2024.03.387. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In nonobstructive hypertrophic cardiomyopathy (nHCM), there are no approved medical therapies. Impaired myocardial energetics is a potential cause of symptoms and exercise limitation. Ninerafaxstat, a novel cardiac mitotrope, enhances cardiac energetics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To evaluate the safety and efficacy of ninerafaxstat in nHCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with HCM and left ventricular (LV) outflow gradient &lt;30 mmHg, ejection fraction ≥50% and peak VO<sub>2</sub> &lt;80% predicted, were randomized to ninerafaxstat 200 mg BID or placebo (1:1) for 12 weeks. Primary endpoint was safety and tolerability with efficacy outcomes also assessed as secondary endpoints.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 67 patients with nHCM were enrolled at 12 centers (57 yrs ± 11.8; 55% women). Serious adverse events occurred in 11.8% (4/34) in the ninerafaxstat group and 6.1% of patients (2/33) in placebo. From baseline to 12 weeks, ninerafaxstat was associated with significantly better ventilatory efficiency (V<sub>E</sub>/VCO<sub>2</sub> slope) compared to placebo with a least square (LS) mean difference between the groups of -2.1 (95% CI, -3.4, -0.6; p=0.006), with no significant difference in pVO<sub>2</sub> (p=0.9). KCCQ-CCS was directionally though not significantly improved with ninerafaxstat vs. placebo (LS mean, 3.2 [95% CI, -2.9, 9.2; p=0.2]), though was statistically significant when analyzed post-hoc in the 35 patients with baseline KCCQ-CSS ≤80 (LS mean, 9.4 [95% CI, 0.2, 18.5; p=0.04]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In symptomatic nHCM, novel drug therapy targeting myocardial energetics was safe and well tolerated and associated with better exercise performance and health status among those most symptomatically limited. The findings support assessing ninerafaxstat in a Phase 3 study.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599256/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599256</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.387>10.1016/j.jacc.2024.03.387</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599256</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Masliza Mahmod</dc:creator>
<dc:creator>Azlan Helmy Abd Samat</dc:creator>
<dc:creator>Lubna Choudhury</dc:creator>
<dc:creator>Daniele Massera</dc:creator>
<dc:creator>Dermot M J Phelan</dc:creator>
<dc:creator>Sharon Cresci</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Theodore P Abraham</dc:creator>
<dc:creator>Eric Adler</dc:creator>
<dc:creator>Omar Wever-Pinzon</dc:creator>
<dc:creator>Sherif F Nagueh</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>Paul Chamberlin</dc:creator>
<dc:creator>Jai Patel</dc:creator>
<dc:creator>Arash Yavari</dc:creator>
<dc:creator>Hakim-Moulay Dehbi</dc:creator>
<dc:creator>Rizwan Sarwar</dc:creator>
<dc:creator>Betty Raman</dc:creator>
<dc:creator>Ladislav Valkovič</dc:creator>
<dc:creator>Stefan Neubauer</dc:creator>
<dc:creator>James E Udelson</dc:creator>
<dc:creator>Hugh Watkins</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38599256</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.387</dc:identifier>
</item>
<item>
<title>A pan-cancer analysis of the microbiome in metastatic cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599211/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>Microbial communities are resident to multiple niches of the human body and are important modulators of the host immune system and responses to anticancer therapies. Recent studies have shown that complex microbial communities are present within primary tumors. To investigate the presence and relevance of the microbiome in metastases, we integrated mapping and assembly-based metagenomics, genomics, transcriptomics, and clinical data of 4,160 metastatic tumor biopsies. We identified...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 5:S0092-8674(24)00312-X. doi: 10.1016/j.cell.2024.03.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Microbial communities are resident to multiple niches of the human body and are important modulators of the host immune system and responses to anticancer therapies. Recent studies have shown that complex microbial communities are present within primary tumors. To investigate the presence and relevance of the microbiome in metastases, we integrated mapping and assembly-based metagenomics, genomics, transcriptomics, and clinical data of 4,160 metastatic tumor biopsies. We identified organ-specific tropisms of microbes, enrichments of anaerobic bacteria in hypoxic tumors, associations between microbial diversity and tumor-infiltrating neutrophils, and the association of Fusobacterium with resistance to immune checkpoint blockade (ICB) in lung cancer. Furthermore, longitudinal tumor sampling revealed temporal evolution of the microbial communities and identified bacteria depleted upon ICB. Together, we generated a pan-cancer resource of the metastatic tumor microbiome that may contribute to advancing treatment strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599211/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38599211</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.021>10.1016/j.cell.2024.03.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599211</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas W Battaglia</dc:creator>
<dc:creator>Iris L Mimpen</dc:creator>
<dc:creator>Joleen J H Traets</dc:creator>
<dc:creator>Arne van Hoeck</dc:creator>
<dc:creator>Laurien J Zeverijn</dc:creator>
<dc:creator>Birgit S Geurts</dc:creator>
<dc:creator>Gijs F de Wit</dc:creator>
<dc:creator>Michaël Noë</dc:creator>
<dc:creator>Ingrid Hofland</dc:creator>
<dc:creator>Joris L Vos</dc:creator>
<dc:creator>Sten Cornelissen</dc:creator>
<dc:creator>Maartje Alkemade</dc:creator>
<dc:creator>Annegien Broeks</dc:creator>
<dc:creator>Charlotte L Zuur</dc:creator>
<dc:creator>Edwin Cuppen</dc:creator>
<dc:creator>Lodewyk Wessels</dc:creator>
<dc:creator>Joris van de Haar</dc:creator>
<dc:creator>Emile Voest</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A pan-cancer analysis of the microbiome in metastatic cancer</dc:title>
<dc:identifier>pmid:38599211</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.021</dc:identifier>
</item>
<item>
<title>Cardiovascular disease and cancer: shared risk factors and mechanisms</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38600368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular disease (CVD) and cancer are among the leading causes of morbidity and mortality globally, and these conditions are increasingly recognized to be fundamentally interconnected. In this Review, we present the current epidemiological data for each of the modifiable risk factors shared by the two diseases, including hypertension, hyperlipidaemia, diabetes mellitus, obesity, smoking, diet, physical activity and the social determinants of health. We then review the epidemiological data...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Apr 10. doi: 10.1038/s41569-024-01017-x. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular disease (CVD) and cancer are among the leading causes of morbidity and mortality globally, and these conditions are increasingly recognized to be fundamentally interconnected. In this Review, we present the current epidemiological data for each of the modifiable risk factors shared by the two diseases, including hypertension, hyperlipidaemia, diabetes mellitus, obesity, smoking, diet, physical activity and the social determinants of health. We then review the epidemiological data demonstrating the increased risk of CVD in patients with cancer, as well as the increased risk of cancer in patients with CVD. We also discuss the shared mechanisms implicated in the development of these conditions, highlighting their inherent bidirectional relationship. We conclude with a perspective on future research directions for the field of cardio-oncology to advance the care of patients with CVD and cancer.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38600368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38600368</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01017-x>10.1038/s41569-024-01017-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38600368</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicholas S Wilcox</dc:creator>
<dc:creator>Uri Amit</dc:creator>
<dc:creator>Jacob B Reibel</dc:creator>
<dc:creator>Eva Berlin</dc:creator>
<dc:creator>Kendyl Howell</dc:creator>
<dc:creator>Bonnie Ky</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cardiovascular disease and cancer: shared risk factors and mechanisms</dc:title>
<dc:identifier>pmid:38600368</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01017-x</dc:identifier>
</item>
<item>
<title>Canonical and non-canonical roles of complement in atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38600367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular diseases are the leading cause of death globally, and atherosclerosis is the major contributor to the development and progression of cardiovascular diseases. Immune responses have a central role in the pathogenesis of atherosclerosis, with the complement system being an acknowledged contributor. Chronic activation of liver-derived and serum-circulating canonical complement sustains endothelial inflammation and innate immune cell activation, and deposition of complement activation...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Apr 10. doi: 10.1038/s41569-024-01016-y. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular diseases are the leading cause of death globally, and atherosclerosis is the major contributor to the development and progression of cardiovascular diseases. Immune responses have a central role in the pathogenesis of atherosclerosis, with the complement system being an acknowledged contributor. Chronic activation of liver-derived and serum-circulating canonical complement sustains endothelial inflammation and innate immune cell activation, and deposition of complement activation fragments on inflamed endothelial cells is a hallmark of atherosclerotic plaques. However, increasing evidence indicates that liver-independent, cell-autonomous and non-canonical complement activities are underappreciated contributors to atherosclerosis. Furthermore, complement activation can also have atheroprotective properties. These specific detrimental or beneficial contributions of the complement system to the pathogenesis of atherosclerosis are dictated by the location of complement activation and engagement of its canonical versus non-canonical functions in a temporal fashion during atherosclerosis progression. In this Review, we summarize the classical and the emerging non-classical roles of the complement system in the pathogenesis of atherosclerosis and discuss potential strategies for therapeutic modulation of complement for the prevention and treatment of atherosclerotic cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38600367/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38600367</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01016-y>10.1038/s41569-024-01016-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38600367</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Pasquale Maffia</dc:creator>
<dc:creator>Claudio Mauro</dc:creator>
<dc:creator>Ayden Case</dc:creator>
<dc:creator>Claudia Kemper</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Canonical and non-canonical roles of complement in atherosclerosis</dc:title>
<dc:identifier>pmid:38600367</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01016-y</dc:identifier>
</item>
<item>
<title>Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38598228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Large TET2 and ASXL1, but not DNMT3A, CHIP was associated with higher IL-6 level, indices of cardiac remodeling, and increased risk for AF. Future research is needed to elaborate on the mechanisms driving the associations and to investigate potential interventions to reduce the risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 10. doi: 10.1001/jamacardio.2024.0459. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Clonal hematopoiesis of indeterminate potential (CHIP) may contribute to the risk of atrial fibrillation (AF) through its association with inflammation and cardiac remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether CHIP was associated with AF, inflammatory and cardiac biomarkers, and cardiac structural changes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a population-based, prospective cohort study in participants of the Atherosclerosis Risk in Communities (ARIC) study and UK Biobank (UKB) cohort. Samples were collected and echocardiography was performed from 2011 to 2013 in the ARIC cohort, and samples were collected from 2006 to 2010 in the UKB cohort. Included in this study were adults without hematologic malignancies, mitral valve stenosis, or previous mitral valve procedure from both the ARIC and UKB cohorts; additionally, participants without hypertrophic cardiomyopathy and congenital heart disease from the UKB cohort were also included. Data analysis was completed in 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: CHIP (variant allele frequency [VAF] ≥2%), common gene-specific CHIP subtypes (DNMT3A, TET2, ASXL1), large CHIP (VAF ≥10%), inflammatory and cardiac biomarkers (high-sensitivity C-reactive protein, interleukin 6 [IL-6], IL-18, high-sensitivity troponin T [hs-TnT] and hs-TnI, N-terminal pro-B-type natriuretic peptide), and echocardiographic indices.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME MEASURE: Incident AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 199 982 adults were included in this study. In ARIC participants (4131 [2.1%]; mean [SD] age, 76 [5] years; 2449 female [59%]; 1682 male [41%]; 935 Black [23%] and 3196 White [77%]), 1019 had any CHIP (24.7%), and 478 had large CHIP (11.6%). In UKB participants (195 851 [97.9%]; mean [SD] age, 56 [8] years; 108 370 female [55%]; 87 481 male [45%]; 3154 Black [2%], 183 747 White [94%], and 7971 other race [4%]), 11 328 had any CHIP (5.8%), and 5189 had large CHIP (2.6%). ARIC participants were followed up for a median (IQR) period of 7.0 (5.3-7.7) years, and UKB participants were followed up for a median (IQR) period of 12.2 (11.3-13.0) years. Meta-analyzed hazard ratios for AF were 1.12 (95% CI, 1.01-1.25; P = .04) for participants with vs without large CHIP, 1.29 (95% CI, 1.05-1.59; P = .02) for those with vs without large TET2 CHIP (seen in 1340 of 197 209 [0.67%]), and 1.45 (95% CI, 1.02-2.07; P = .04) for those with vs without large ASXL1 CHIP (seen in 314 of 197 209 [0.16%]). Large TET2 CHIP was associated with higher IL-6 levels. Additionally, large ASXL1 was associated with higher hs-TnT level and increased left ventricular mass index.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Large TET2 and ASXL1, but not DNMT3A, CHIP was associated with higher IL-6 level, indices of cardiac remodeling, and increased risk for AF. Future research is needed to elaborate on the mechanisms driving the associations and to investigate potential interventions to reduce the risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38598228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38598228</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0459>10.1001/jamacardio.2024.0459</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38598228</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Seyedmohammad Saadatagah</dc:creator>
<dc:creator>Mohammadreza Naderian</dc:creator>
<dc:creator>Mesbah Uddin</dc:creator>
<dc:creator>Ozan Dikilitas</dc:creator>
<dc:creator>Abhishek Niroula</dc:creator>
<dc:creator>Art Schuermans</dc:creator>
<dc:creator>Elizabeth Selvin</dc:creator>
<dc:creator>Ron C Hoogeveen</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:creator>Vijay Nambi</dc:creator>
<dc:creator>Bing Yu</dc:creator>
<dc:creator>Lin Yee Chen</dc:creator>
<dc:creator>Alexander G Bick</dc:creator>
<dc:creator>Benjamin L Ebert</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:creator>Na Li</dc:creator>
<dc:creator>Amil Shah</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Iftikhar J Kullo</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1</dc:title>
<dc:identifier>pmid:38598228</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0459</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38597985/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 1;9(4):312. doi: 10.1001/jamacardio.2023.3655.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38597985/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38597985</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3655>10.1001/jamacardio.2023.3655</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38597985</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:38597985</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3655</dc:identifier>
</item>
<item>
<title>Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38597864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411021122&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among individuals with DbCM and impaired exercise capacity, treatment with AT-001 for 15 months did not result in significantly better exercise capacity compared with placebo. (Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy [ARISE-HF]; NCT04083339).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 3:S0735-1097(24)06613-0. doi: 10.1016/j.jacc.2024.03.380. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Progression to symptomatic heart failure is a complication of type 2 diabetes; heart failure onset in this setting is commonly preceded by deterioration in exercise capacity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The study sought to determine whether AT-001, a highly selective aldose reductase inhibitor, can stabilize exercise capacity among individuals with diabetic cardiomyopathy (DbCM) and reduced peak oxygen uptake (Vo<sub>2</sub>).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 691 individuals with DbCM meeting inclusion and exclusion criteria were randomized to receive placebo or ascending doses of AT-001 twice daily. Stratification at inclusion included region of enrollment, cardiopulmonary exercise test results, and use of sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists. The primary endpoint was proportional change in peak Vo<sub>2</sub> from baseline to 15 months. Subgroup analyses included measures of disease severity and stratification variables.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean age was 67.5 ± 7.2 years, and 50.4% of participants were women. By 15 months, peak Vo<sub>2</sub> fell in the placebo-treated patients by -0.31 mL/kg/min (P = 0.005 compared to baseline), whereas in those receiving high-dose AT-001, peak Vo<sub>2</sub> fell by -0.01 mL/kg/min (P = 0.21); the difference in peak Vo<sub>2</sub> between placebo and high-dose AT-001 was 0.30 (P = 0.19). In prespecified subgroup analyses among those not receiving sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists at baseline, the difference between peak Vo<sub>2</sub> in placebo vs high-dose AT-001 at 15 months was 0.62 mL/kg/min (P = 0.04; interaction P = 0.10).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among individuals with DbCM and impaired exercise capacity, treatment with AT-001 for 15 months did not result in significantly better exercise capacity compared with placebo. (Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy [ARISE-HF]; NCT04083339).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38597864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411021122&v=2.18.0.post9+e462414">38597864</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.380>10.1016/j.jacc.2024.03.380</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38597864</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Stefano Del Prato</dc:creator>
<dc:creator>Justin A Ezekowitz</dc:creator>
<dc:creator>Nasrien E Ibrahim</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>Thomas H Marwick</dc:creator>
<dc:creator>Riccardo Perfetti</dc:creator>
<dc:creator>Julio Rosenstock</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38597864</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.380</dc:identifier>
</item>





























</channel>
</rss>